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JOURNAL OF HEPATOLOGYTo the Editor:
Features of both primary sclerosing cholangitis (PSC) and autoim-
mune hepatitis (AIH) in the same patient were ﬁrst described
about 2 decades ago, including a small ﬁrst case series published
in the Journal of Hepatology in 1996 by Gohlke et al. [1,2]. Most
notably, at ﬁrst diagnosis all three patients from this early report
fulﬁlled the criteria for a deﬁnite (patient 1 and 2) or probable
(patient 3) AIH, according to the scoring system of the Interna-
tional Autoimmune Hepatitis Group (IAIHG) from 1993 [3], but
responded insufﬁciently to immunosuppression, particularly
with respect to cholestatic biochemical parameters. Therefore
in all patients a retrograde endoscopic cholangiography was per-
formed, showing a peripheral bile duct rareﬁcation and multiple
strictures and dilatations of the intra- (patients 1–3) and extrahe-
patic (patient 3) bile ducts. Additionally, early follow-up liver
biopsy in two patients detected portal ﬁbrosis with ﬁbrous oblit-
erative cholangitis and a reduction of bile ducts (patient 1) and a
progression to liver cirrhosis with rareﬁcation of bile ducts and
partly onion-like periductular ﬁbrosis (patient 3), respectively
The ﬁndings strongly suggested that from the beginning these
patients were affected not only by AIH but also by cholangiopa-
thy. Under the assumption of an ‘‘overlap syndrome’’ between
PSC and AIH ursodeoxycholic acid (UDCA) was therefore added
to the immunosuppressive regime and cholestatic biochemical
parameters decreased.
Since this early report, there has been an increasing aware-
ness for patients with features of both conditions, often called
‘‘PSC/AIH overlap’’, and nowadays overlapping features are
widely accepted to constitute a variant of the primary disorder
mostly PSC, rather than a separate disease entity. This, indeed
is a renunciation from the original term of the ‘‘overlap syn-
drome’’ and a consequence of a lack of speciﬁc diagnostic tests
evidence based treatment strategies and implications for progno-
sis [4]. In fact, despite some larger cohorts published on this issue
in the last years [5–8], data on PSC/AIH overlap patients are
scarce and the long-term outcome is not well characterized
underlining that follow-up data focussing on this special patient
cohort are required. Therefore, we here report the long-term
follow-up of the three cases originally published by Gohlke
et al. in 1996 [1].
The most important message is, that all patients (patients
1–3) are still alive 22, 27, and 25 years after ﬁrst presentation –
yet disease has been progressive in all three cases despite a
combined regime of immunosuppression and UDCA (Table 1)
In patient 1, the further clinical course was characterized by
progressive bile duct destruction recently treated by balloon
dilatation with partial success. The therapeutic regime with
azathioprine and UDCA has been continued until today. Still
20 years after the ﬁrst presentation, follow-up liver biopsy
demonstrated an incomplete biliary cirrhosis, while at the same
time oesophageal varices were ﬁrst diagnosed in this patient
Due to these ﬁndings and a progressive weight loss, the patient
has now been listed for liver transplantation. In patient 2, bile
duct interventions due to dominant strictures were required in
the ﬁrst years after diagnosis. While the patient’s condition isJournal of Hepatology 2014
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clinically stable at the moment, as is his ulcerative colitis, a fol-
low-up liver biopsy 17 years after the initial diagnosis showed
beginning liver cirrhosis based on destructive cholangitis. Since
portal hepatitis was mostly inactive, immunosuppressive treat-
ment with azathioprine was stopped and the present treatment
is limited to UDCA and mesalazine. As in patient 1, recent labora-
tory ﬁndings showed a distinct elevation of cholestatic biochem-
ical parameters while aminotransferase levels were normal or
only slightly elevated. Still, patient 2 has developed oesophageal
varices and is listed for liver transplantation, as well. Until now,
only in patient 3 liver transplantation has been performed –
22 years after the ﬁrst diagnosis due to progressive bile duct
destruction and liver cirrhosis. The examination of the explanted
liver showed a complete cirrhosis with bile duct inﬂammation
and ﬁbrosis. The immunosuppressive regime, which included
azathioprine until transplantation, now consists of tacrolimus
and prednisolone. So far, there are no signs of recurrence of the
original liver disease and the patient’s physical condition is excel-
lent. None of the three patients have developed malignancy until
today, nor has an incidental tumour been observed in the
explanted liver of patient 3.
With up to 27 years, we here report the longest follow-up ever
published on the PSC/AIH ‘‘overlap syndrome’’ so far. In all
patients, the original diagnosis was AIH. However, all patients
insufﬁciently responded to immunosuppressive therapy and
eventually showed typical signs of a large duct PSC. The further
course of the liver disease was primarily characterized by bile
duct destruction rather than by hepatitis or decompensation of
liver cirrhosis, underlining that PSC was the primary disorder.
In inﬂammatory or aggressive PSC, as PSC/AIH overlap is now
regarded, one would expect a poorer prognosis than in patients
with straight forward PSC. However, the clinical course of these
patients so far appears to be comparably benign with only one
patient receiving liver transplantation after a relatively long
observation period of 22 years and a transplant-free survival of
22 and 27 years of the other patients. Indeed, there is increasing
evidence for a better outcome of PSC/AIH overlap compared to
classical PSC patients, most notably demonstrated in a prospec-
tive case-control study by Floreani et al. where patients’ survival
was better when an overlap between both diseases was present
[6]. What may be the reasons behind this proposed better out-
come of the overlap patients? A major feature of both PSC/AIH
overlap cohorts – the patients reported by Floreani et al. and
our patients, separating them from classical PSC patients, is the
use of immunosuppression, which for the vast majority of
patients consisted of azathioprine and steroids. Most authors rate
this regime as beneﬁcial for the AIH component only [4]. This, in
fact, would implicate a comparably poor outcome of PSC/AIH
overlap and classical PSC patients. However, a better outcome
of the overlap patients would indicate, that immunosuppression
may beneﬁt both conditions – the AIH and the PSC component, as
well. In fact, even though data available on this issue are
scarce and conﬂicting [9], there is evidence that a combined
regime of azathioprine, steroids and UDCA positively effects
disease progression in classical PSC also [10]. This, indeed, would
vol. 61 j 1184–1191 1189
ﬁt the concept of a putative autoimmune liver disease. Still, case
numbers particularly of the series presented here are too small to
draw any ﬁrm conclusions from the available data. Thus, the
long-term outcome and the role of immunosuppression in
patients with an overlap of both PSC and AIH need to be
elucidated further.
Summarized, the long-term follow-up of this very ﬁrst case
series suggests that the clinical course of patients with
overlapping features between PSC and AIH seems to be better
than in classical PSC, indicating that immunosuppression might
have a positive effect on the progression of the PSC component.
As particularly in classical PSC the prognosis is severe and
treatment options are strongly needed, controlled trials with
a combination of azathioprine, steroids and UDCA appear
warranted.
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Table 1. Long-term follow-up data of PSC/AIH overlap patients.
Patient
(follow-up time)
IBD Initial liver biopsy/early 
follow-up liver biopsy
Recent 
follow-up liver 
biopsy
Therapeutic 
regime
Clinical events
Before
start IS*
After
Laboratory findings
start IS*
Most
recent
Patient 1
(22 yr)
No AST
ALT 
GGT
ALP
Bilirubin
IgG
ANA 
SMA 
232
738
246 
914
2.2
26.7
1:320 
1:640 
-
21
106
189
0.6
10.3
negative
negative
146
87
359
684
8.3
12.7
-
-
Chronic active hepatitis 
with bridging necrosis/
mild parenchymatous 
inflammation with
bile duct proliferation
periductular fibrosis and
Incomplete 
biliary 
cirrhosis, 
minor 
(20 yr after 
inflammation
diagnosis)
UDCA/
azathioprine 
since first
diagnosis
Dominant 
strictures, 
esophageal 
varices, weight 
loss
Patient 2
(27 yr)
Yes
(UC)
AST
ALT
GGT
ALP
Bilirubin
IgG 
ANA 
SMA
104
119
173
1202
0.86
25.7
1:40
neg.
-
12
105
96
0.6
22.2
negative
negative
48
42
34
146
2.31
-
-
-
Piecemeal necrosis with 
portal infiltration and early
fibrosis/-
Beginning 
cirrhosis, 
bile duct 
proliferation, 
inactive portal 
hepatitis 
(17 yr after 
diagnosis)
UDCA since 
first diagnosis,
from first
azathioprine 
diagnosis until 
recent follow-
up biopsy
Dominant 
strictures - 
recently stable, 
esophageal 
varices
Patient 3
(25 yr)
No AST 
ALT 
GGT 
ALP
Bilirubin
IgG 
ANA
SMA
292
292
472
577
2.7
20.6
1:640
1:80
-
23
84
275
2.0
17.0
negative
negative
8
12
23
43
-
-
-
-
Chronic active hepatitis 
with enlarged portal tracts, 
periportal necrosis and 
necroinflammatory activity
with bridging necrosis, 
of bile ducts/liver cirrhosis 
ducts and onion-like 
Complete 
cirrhosis, 
bile duct 
(explanted 
liver, 22 
yr after 
diagnosis) 
UDCA/
azathioprine 
since first
inflammation/
fibrosis
diagnosis until 
transplantation. 
Since then 
tacrolimus/
prednisolone
Liver 
transplantation 
due to biliary 
cirrhosis 
(22 yr after 
diagnosis) inflammatory infiltration
with rarefication of bile
periductular fibrosis
Laboratory parameters (reference rage): ALP, alkaline phosphatase (40–129 U/l); ANA, antinuclear antibody (titre); ALT, alanine aminotransferase (10–50 U/l); AST,
aspartate aminotransferase (10–50 U/l); GGT, gamma-glutamyl transpeptidase (0–65 U/l); Bilirubin (<1.2 mg/dl); IgG, immunoglobulin G (7–16 g/l); SMA, smooth muscle
antibody (titre).
IBD, inﬂammatory bowel disease; UC, ulcerative colitis.
⁄Before/1 year after start with immunosuppression with azathioprine (1–1.5 mg/kg) and prednisolone (1 mg/kg, initial dosis) in combination with ursodeoxycholic acid
(UDCA).
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